Chlamydia Diagnostics Market By Test Type (Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, Others), By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2027

Report Code: HCR 0850 Report Format: PDF + Excel
Chlamydia Diagnostics Market Overview

Chlamydia Diagnostics Market size is estimated to reach $3.5 billion by 2027, growing at a CAGR of 7.8% during the forecast period 2022-2027. Chlamydia Infection is a typical sexually transmitted infection brought about by bacteria. There are no symptoms in the beginning phases. However, health issues can be brought about at a subsequent phase. Chlamydia diagnostics involves testing with a urethral swab, a swab of the cervix or vagina, or a urine test. There is no way to self-test for chlamydia infection. As per updates by the Centers For Disease Control And Prevention (CDC), owing to apprehensions with reference to chlamydia persistence subsequent to exposure to penicillin-class antibiotics that have been established in animal and in vitro investigations, amoxicillin is listed as a substitute therapy for C. trachomatis for pregnant women (828,829). The favorite technique for chlamydia testing is the nucleic acid amplification test that discovers the genetic material of Chlamydia trachomatis. It is typically more sensitive and specific than additional chlamydia tests and can be carried out on a vaginal swab on women or urine from both men and women, which removes the requirement for a pelvic exam in women. In the direct fluorescent antibody method, a smear of the sample is incubated with a solution including a particular antibody that is directly labeled with a fluorescent dye. The initial antigen detection test was the direct fluorescent antibody test (DFA), which inexperienced laboratories had a specificity of 99.6%, however, its sensitivity was only 61% in comparison with culture. The development of greatly sensitive and particular Polymerase Chain Reaction (PCR) assays has made the DFA test out-of-date. The commercially accessible serology tests involve the complement fixation (CF) test, the microimmunofluorescence (MIF) test, and the enzyme-linked immunosorbent assay (ELISA). The CF test has conventionally been utilized to diagnose chlamydial respiratory infections (32, 39).

The increasing predominance of chlamydia infections is set to drive the Chlamydia Diagnostics Market. The budding demand for rapid testing and serology tests is set to propel the growth of the Chlamydia Diagnostics Market during the forecast period 2022-2027. This represents the Chlamydia Diagnostics Industry Outlook.

Report Coverage

The report: Chlamydia Diagnostics Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Chlamydia Diagnostics Market.

By Test Type: Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, Others.
By End User: Hospitals, Specialty Clinics, Diagnostic Centers, Others.
By Geography: North America (U.S, Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), and Rest Of The World (Middle East, Africa).

Key Takeaways

  • Geographically, North America Chlamydia Diagnostics Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the surging healthcare awareness including awareness of serology tests and reimbursement facilities for chlamydia diagnostics in conjunction with considerable healthcare expenditure in complete national budgets in the North American region.
  • Chlamydia Diagnostics Market growth is being driven by the surging count of screenings for chlamydia infections among pregnant women involving serology tests if required and proliferating government initiatives and supportive reimbursements for chlamydia screening. However, the awareness regarding diagnostic tests for chlamydia infections is exceedingly low in African nations restraining the market penetration of firms and this is one of the major factors hampering the growth of Chlamydia Diagnostics Market. 
  • Chlamydia Diagnostics Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Chlamydia Diagnostics Market report

Chlamydia Diagnostics Market: Market Share (%) by Region, 2021

Chlamydia Diagnostics Market

For More Details on This Report - Request for Sample

Chlamydia Diagnostics Market Segment Analysis – By Test Type

The Chlamydia Diagnostics Market based on test type can be further segmented into Culture Tests, Nucleic Acid Amplification tests (NAAT), Direct Fluorescent Antibody tests, and Serology Tests, Others. The Nucleic Acid Amplification Test (NAAT) Segment held the largest market share in 2021. This growth is owing to the proliferating application of the Nucleic Acid Amplification Test (NAAT) which is a molecular test for the discovery of DNA, the genetic material of Chlamydia trachomatis. The development of novel diagnostic tools with focused financing and endeavors is further propelling the growth of the Nucleic Acid Amplification Test (NAAT) segment.

Furthermore, the Serology Tests segment is estimated to grow with the fastest CAGR of 8.2% during the forecast period 2022-2027 owing to the surging application of serology tests like microimmunofluorescence (micro-IF) test which is not only a very sensitive technique but can also achieve a soaring degree of serodiagnostic specificity in some chlamydial contagions.

Chlamydia Diagnostics Market Segment Analysis – By End User

The Chlamydia Diagnostics Market based on end-user can be further segmented into Hospitals, Specialty Clinics, Diagnostic Centers, and Others. The Hospitals segment held the largest market share in 2021. This growth is owing to the effortless accessibility of progressive infrastructure and qualified physicians together with the enormous count of patients visiting hospitals for treatment. Nucleic Acid Amplification Test (NAAT) is the preferred test for the discovery of Chlamydia. The effortless accessibility of screening tests to detect chlamydia in hospitals is further propelling the growth of this segment.

Furthermore, the Diagnostic Centers segment is estimated to grow with the fastest CAGR of 8.4% during the forecast period 2022-2027 owing to the surging application of rapid molecular diagnosis of Chlamydia Trachomatis in specialized diagnostic centers including the application of Nucleic Acid Amplification Tests (NAATs).

Chlamydia Diagnostics Market Segment Analysis – By Geography

The Chlamydia Diagnostics Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and Rest of the World. North America (Chlamydia Diagnostics Market) held the largest share with 37% of the overall market in 2021. The growth of this region is owing to the early accessibility of progressive technologies and greater penetration of research activities nationwide in the North American region. Nucleic acid amplification tests are regarded as the preferred test for the detection of chlamydia. The soaring rate of diagnosis and great awareness among the people are further propelling the growth of the Chlamydia Diagnostics Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the increasing predominance of sexually-transmitted diseases, blood infections, and diarrhoeal infections in the Asia-Pacific region. Nucleic acid amplification tests are considered the diagnostic gold standard for the detection of chlamydia. The soaring demand for rapid testing is further fuelling the progress of the Chlamydia Diagnostics Market in the Asia-Pacific region.

Chlamydia Diagnostics Market - Drivers

Surging Applications Of Nucleic Acid Amplification Test (NAAT) As Part of Chlamydia Diagnostics Are Projected To Drive The Growth Of Chlamydia Diagnostics Market:

As per the Centers For Disease Control And Prevention (CDC), chlamydia is most typically observed among young people and two-thirds of novel chlamydial contaminations happen among youth with age between 15-24 years. Nucleic Acid Amplification Tests (NAATs) are the most sensitive tests to discover chlamydia. These tests also possess a high specificity commensurate to culture, however, in contrast to culture, do not rely on practicable pathogens, expediting specimen transport. Therefore, NAATs are typically regarded as the test of choice for chlamydia and have dislodged culture as the diagnostic gold standard. Antigen tests (EIA, DFA, RDTs) are no longer suggested for chlamydia testing owing to inadequate diagnostic accuracy. Nearly all of the NAATs are based on polymerase chain reaction (PCR) and utilize fluorescence-labeled probes to discover amplification products in real-time, thereby considerably decreasing the test duration. Integrated with automated nucleic acid extraction, outcomes can be produced in a few hours. In a number of investigations, outcomes of distinct NAATs were demonstrated to be greatly concordant The surging applications of nucleic acid amplification test (NAAT) as part of chlamydia diagnostics are therefore fuelling the growth of the Chlamydia Diagnostics Market during the forecast period 2022-2027.

Proliferating Applications Of Serology Tests As Part Of Chlamydia Diagnostics Are Expected To Boost The Demand In the Chlamydia Diagnostics Market:

As per estimates by the Centers for Disease Control And Prevention (CDC), 1 in 20 sexually active young women between the ages of 14-24 years has chlamydia. Until ten years back, the complement-fixation test evaluating group-specific antibodies was the most extensively used method. However, in spite of demonstrating comparatively high diagnostic sensitivity in systemic chlamydial contaminations, it is of limited value in the serodiagnosis of localized chlamydial ocular-genital contaminations or of trachoma. The more currently developed microimmunofluorescence (micro-IF) test is not only a very sensitive method but can also attain a soaring degree of serodiagnostic specificity in some chlamydial contaminations. Unlike the complement-fixation test, it evaluates type-specific antibodies which may be aimed against one or more C trachomatis serotypes. In seroepidemiological work, in the investigation of transmission patterns, and in the discovery of predominant serotypes in a community, the micro-IF test is specifically valuable, and if outcomes are interpreted with care, the test may also act as an indicator of chlamydial contamination. The proliferating applications of serology tests as part of chlamydia diagnostics are therefore driving the growth of the Chlamydia Diagnostics Market during the forecast period 2022-2027.

Chlamydia Diagnostics Market – Challenges

Disadvantages Of Screening Tests And Nucleic Acid Amplification Tests (NAATs) Are Hampering The Growth Of The Chlamydia Diagnostics Market:

As per the Centers For Disease Control And Prevention (CDC), “in 2020, chlamydia rates for African Americans/Blacks were six times that of Whites”. Investigations have indicated that when C. trachomatis infection was defined by numerous tests from distinct specimen sources, the sensitivity of any 1 test from a single specimen source was reduced than typically recorded. The disadvantages of the application of a single test to recognize C. trachomatis infection should be regarded when test type, specimen source, and collection technique for screening young women are being concluded. Though Nucleic Acid Amplification Tests (NAATs) are sensitive, multiple limitations have been described. The first is that they are high-priced and therefore may not be affordable by health departments for all-inclusive screening. Another limitation is that the FDA-approved NAATs cannot differentiate LGV from non-LGV strains, which is significant owing to the period of treatment being lengthier for LGV infections. Additionally, NAATs discover chlamydial DNA or RNA instead of living organisms, and positive NAAT outcomes are not uncommon 3 weeks subsequent to finishing of antibiotic therapy. Therefore, NAATs should not be utilized as a test-of-cure assay, except in pregnant women in whom it is justified to document cure at 3-4 weeks subsequent to finishing of therapy in an endeavor to avoid infection in the baby. These issues are thus the growth of the Chlamydia Diagnostics Market.

Chlamydia Diagnostics Industry Outlook:

Novel product launches, mergers and acquisitions, asset transactions and business expansions are key strategies adopted by players in the Chlamydia Diagnostics Market. Key companies of this market are:

  1. Abbott Laboratories
  2. F. Hoffmann La Roche Ltd
  3. Hologic, Inc.
  4. Quidel Corporation
  5. DiaSorin SpA
  6. Bio Rad Laboratories
  7. Novartis AG
  8. Thermo Fisher Scientific
  9. Danaher Corporation
  10. Siemens AG

Recent Developments

  • In January 2022, Roche declared the introduction of the cobas® pulse system in select nations acquiring the CE Mark. The cobas® pulse system symbolizes Roche Diagnostics’ most novel generation of connected point of care solutions for professional blood glucose administration. As an industry first, the cobas® pulse system integrates the form factor of a high-performance blood glucose meter with simple usability and extended digital possibilities comparable to that of a smartphone.
  • In November 2021, Roche declared the introduction of the cobas® 5800 System, a novel molecular laboratory instrument, in nations acquiring the CE mark. Testing is one of the earliest lines of defense to safeguard a patient’s general well-being and is essentially significant in promptly guiding their treatment. The cobas 5800 System assists in attending to challenges that laboratories are encountering from a boost in patient testing, reimbursement complications, and the requirement for a more distinct testing menu while offering meaningful and timely outcomes.
  • In July 2021, Abbott declared the introduction of Panbio™ COVID-19 Antigen Self-Test for the discovery of the SARS-CoV-2 virus in mature grown-ups and children with or without symptoms. In line with the present ICMR advisory on self-application, these tests will be made accessible to ramp up testing of symptomatic and asymptomatic individuals and contacts of verified coronavirus cases. Abbott will distribute millions of Panbio COVID-19 Rapid Antigen Tests accessible for self-application to ease the burden on healthcare systems in urban and rural India.

Related Reports

Nucleic Acid Amplification Testing Market - Forecast 2021 – 2026

Report Code: HCR 73607

Blood Culture Tests Market – Forecast (2022 - 2027)

Report Code: HCR 0073

Cell Culture Market – Forecast (2022 - 2027)

Report Code: HCR 0090

For more Lifesciences and Healthcare Market reports, please click here

1. Chlamydia Diagnostics Market Overview
    1.1 Definitions and Scope
2. Chlamydia Diagnostics Market - Executive Summary
3. Chlamydia Diagnostics Market – Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Chlamydia Diagnostics Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Chlamydia Diagnostics Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Chlamydia Diagnostics Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Chlamydia Diagnostics Market – By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Chlamydia Diagnostics Market - By Test Type (Market Size –$Million/$Billion) 
    8.1 Culture Tests
    8.2 Nucleic Acid Amplification Test (NAAT)
    8.3 Direct Fluorescent Antibody Test
    8.4 Serology Tests
    8.5 Others
9. Chlamydia Diagnostics Market - By End User (Market Size –$Million/$Billion) 
    9.1 Hospitals
    9.2 Specialty Clinics
    9.3 Diagnostic Centers
    9.4 Others
10. Chlamydia Diagnostics Market - By Geography (Market Size -$Million/Billion)
    10.1 North America
        10.1.1 U.S
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 Germany
        10.2.2 France
        10.2.3 UK
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Russia
        10.2.7 Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 Japan
        10.3.3 South Korea
        10.3.4 India
        10.3.5 Australia & New Zealand
        10.3.6 Rest of Asia-Pacific
    10.4 South America
        10.4.1 Brazil
        10.4.2 Argentina
        10.4.3 Chile
        10.4.4 Colombia
        10.4.5 Rest of South America
    10.5 Rest Of The World
        10.5.1 Middle East
        10.5.2 Africa
11. Chlamydia Diagnostics Market - Market Entropy
    11.1 New product launches
    11.2 M&A's, collaborations, JVs and partnerships
12. Chlamydia Diagnostics Market – Industry Competition Landscape (Premium)
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key Companies
        12.1.3 Market Share by Countries – Key Companies
    12.2 Competition Matrix
    12.3 Best Practices for Companies
13. Chlamydia Diagnostics Market – Key Company List by Country Premium (Premium)
14. Chlamydia Diagnostics Market - Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"